University College London, School of Pharmacy, London, UK; Cantabio Pharmaceuticals, Palo Alto, USA; TTK-NAP B - Drug Discovery Research Group - Neurodegenerative Diseases, Institute of Organic Chemistry, Research Center for Natural Sciences, Budapest, Hungary.
University College London, School of Pharmacy, London, UK.
Drug Discov Today. 2021 Oct;26(10):2205-2208. doi: 10.1016/j.drudis.2021.04.027. Epub 2021 May 8.
The level of funding available for research and development (R&D) of diagnostics (D) and therapeutics (T) for incurable diseases varies and is not associated with the extent of their disease burden. Crowdfunding is a promising way to increase funding for R&D of D&T for underfunded incurable diseases, such as Alzheimer's and Parkinson's disease, which has not been exploited to its full capacity. Investing into efforts to educate patients and researchers about its prospective is a worthwhile endeavor, which could lead to the generation of substantial new capital to finance the development of novel therapeutics for these diseases.
用于研发（R&D）无法治愈疾病的诊断（D）和治疗（T）的资金水平各不相同，且与疾病负担的程度无关。众筹是增加对资金不足的无法治愈疾病（如阿尔茨海默病和帕金森病）的诊断和治疗的研发资金的一种很有前景的方式，但尚未充分利用。投入精力对患者和研究人员进行有关众筹的教育是一项有价值的努力，这可能会带来大量新的资金，为这些疾病的新型治疗方法的开发提供资金。
